DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR

Background: Sofosbuvir (SOF) and daclatasvir (DCV) are usually prescribed in combination for the treatment of hepatitis C worldwide. Objectives: In the present study a novel, simple, rapid, and cost-effective reversed-phase high performance liquid chromatography (HPLC) method was developed, optimis...

Full description

Saved in:
Bibliographic Details
Main Authors: Syed Hassan Murtaza, Ahmed Umer Sohaib Ahmed, Tassawer-e-Meran, Sonam Anees, Najam-ul-Hassan Khan, Kishwar Sultana
Format: Article
Language:English
Published: Superior University Lahore, Pakistan 2024-03-01
Series:International Journal of Pharmacy & Integrated Health Sciences
Subjects:
Online Access:https://ijpihs.pk/index.php/IJPIHS/article/view/118
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849422201462194176
author Syed Hassan Murtaza
Ahmed Umer Sohaib Ahmed
Tassawer-e-Meran
Sonam Anees
Najam-ul-Hassan Khan
Kishwar Sultana
author_facet Syed Hassan Murtaza
Ahmed Umer Sohaib Ahmed
Tassawer-e-Meran
Sonam Anees
Najam-ul-Hassan Khan
Kishwar Sultana
author_sort Syed Hassan Murtaza
collection DOAJ
description Background: Sofosbuvir (SOF) and daclatasvir (DCV) are usually prescribed in combination for the treatment of hepatitis C worldwide. Objectives: In the present study a novel, simple, rapid, and cost-effective reversed-phase high performance liquid chromatography (HPLC) method was developed, optimised, and validated for simultaneous analysis of sofosbuvir and daclatasvir in human plasma as well as in solid dosage forms. Methodology: The chromatographic analyses were carried out using Shimadzu HPLC gradient system (LC20), while the other HPLC system used for the peak purity and repeated validation studies was Agilent 1260 Infinity fitted with diode array detector. The column used was C18 (150 × 4.6 mm; 5 µm), from Agela Technologies. The mobile phase consisted of acetonitrile and 0.02 M potassium Hexafluorophosphate buffer (42:58, v/v) at pH 2.7, pumped at the rate of 1.3 mL min−1. The limit of detection and limit of quantification were determined using dilution method (RSD/m formula). Results: SOF and DCV combination therapy is significant for the treatment of hepatitis C. Development of this RP-HPLC method for the simultaneous determination and quantification of SOF and DCV is a part of an extensive project of novel formulation development (fixed dose combination tablets of SOF and DCV). This method is successfully applied for raw materials as well as in combination tablets. This method may also be applied for the quantification of sofosbuvir and daclatasvir in blood samples of patients taking these two antivirals for hepatitis C treatment. Conclusion: The optimized method was successfully applied for the determination of sofosbuvir and daclatasvir in single run without any interference. Hence, the developed method is quite appropriate for the simultaneous determination of SOF and DCV in solid dosage form as well as in human plasma for clinical research studies.
format Article
id doaj-art-2f33afa5ea254019b0f18bd10f95db88
institution Kabale University
issn 2958-1656
2789-2840
language English
publishDate 2024-03-01
publisher Superior University Lahore, Pakistan
record_format Article
series International Journal of Pharmacy & Integrated Health Sciences
spelling doaj-art-2f33afa5ea254019b0f18bd10f95db882025-08-20T03:31:11ZengSuperior University Lahore, PakistanInternational Journal of Pharmacy & Integrated Health Sciences2958-16562789-28402024-03-015110.56536/ijpihs.v5i1.118DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIRSyed Hassan Murtaza0Ahmed Umer Sohaib Ahmed1Tassawer-e-Meran2Sonam Anees3Najam-ul-Hassan Khan4Kishwar Sultana5Faculty of Pharmacy, The University of Lahore, Lahore PakistanFaculty of Pharmacy, The University of Lahore, Lahore PakistanYashfeen College of Pharmacy, Lahore, PakistanUniversity College of Pharmacy, University of the Punjab, Lahore, PakistanFaculty of Pharmacy, The University of Lahore, Lahore PakistanFaculty of Pharmacy, The University of Lahore, Lahore Pakistan Background: Sofosbuvir (SOF) and daclatasvir (DCV) are usually prescribed in combination for the treatment of hepatitis C worldwide. Objectives: In the present study a novel, simple, rapid, and cost-effective reversed-phase high performance liquid chromatography (HPLC) method was developed, optimised, and validated for simultaneous analysis of sofosbuvir and daclatasvir in human plasma as well as in solid dosage forms. Methodology: The chromatographic analyses were carried out using Shimadzu HPLC gradient system (LC20), while the other HPLC system used for the peak purity and repeated validation studies was Agilent 1260 Infinity fitted with diode array detector. The column used was C18 (150 × 4.6 mm; 5 µm), from Agela Technologies. The mobile phase consisted of acetonitrile and 0.02 M potassium Hexafluorophosphate buffer (42:58, v/v) at pH 2.7, pumped at the rate of 1.3 mL min−1. The limit of detection and limit of quantification were determined using dilution method (RSD/m formula). Results: SOF and DCV combination therapy is significant for the treatment of hepatitis C. Development of this RP-HPLC method for the simultaneous determination and quantification of SOF and DCV is a part of an extensive project of novel formulation development (fixed dose combination tablets of SOF and DCV). This method is successfully applied for raw materials as well as in combination tablets. This method may also be applied for the quantification of sofosbuvir and daclatasvir in blood samples of patients taking these two antivirals for hepatitis C treatment. Conclusion: The optimized method was successfully applied for the determination of sofosbuvir and daclatasvir in single run without any interference. Hence, the developed method is quite appropriate for the simultaneous determination of SOF and DCV in solid dosage form as well as in human plasma for clinical research studies. https://ijpihs.pk/index.php/IJPIHS/article/view/118SofosbuvirdaclatasvirRP-HPLCoptimizationvalidation
spellingShingle Syed Hassan Murtaza
Ahmed Umer Sohaib Ahmed
Tassawer-e-Meran
Sonam Anees
Najam-ul-Hassan Khan
Kishwar Sultana
DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR
International Journal of Pharmacy & Integrated Health Sciences
Sofosbuvir
daclatasvir
RP-HPLC
optimization
validation
title DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR
title_full DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR
title_fullStr DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR
title_full_unstemmed DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR
title_short DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR
title_sort development and validation of a new rp hplc method for simultaneous determination and quantification of sofosbuvir and daclatasvir
topic Sofosbuvir
daclatasvir
RP-HPLC
optimization
validation
url https://ijpihs.pk/index.php/IJPIHS/article/view/118
work_keys_str_mv AT syedhassanmurtaza developmentandvalidationofanewrphplcmethodforsimultaneousdeterminationandquantificationofsofosbuviranddaclatasvir
AT ahmedumersohaibahmed developmentandvalidationofanewrphplcmethodforsimultaneousdeterminationandquantificationofsofosbuviranddaclatasvir
AT tassaweremeran developmentandvalidationofanewrphplcmethodforsimultaneousdeterminationandquantificationofsofosbuviranddaclatasvir
AT sonamanees developmentandvalidationofanewrphplcmethodforsimultaneousdeterminationandquantificationofsofosbuviranddaclatasvir
AT najamulhassankhan developmentandvalidationofanewrphplcmethodforsimultaneousdeterminationandquantificationofsofosbuviranddaclatasvir
AT kishwarsultana developmentandvalidationofanewrphplcmethodforsimultaneousdeterminationandquantificationofsofosbuviranddaclatasvir